Non-Hodgkin Lymphoma | Specialty

The non-hodgkin lymphoma condition center is a comprehensive resource for clinical news and expert insights on non-hodgkin lymphoma. Read more at OncLive.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Nivolumab-Based, Response-Adapted Approach Yields Durable Responses in Frontline Follicular Lymphoma

April 15th 2025

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Glofitamab Plus Chemo Wins European Approval for R/R DLBCL

April 14th 2025

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma

April 4th 2025

OncologyLive was onsite at the 2024 ASH Annual Meeting to film a Peer Exchange featuring expert commentary on follicular lymphoma.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

April 2nd 2025

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL

April 1st 2025

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse

April 1st 2025

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

Dr Alderuccio on Loncastuximab Tesirine Plus Rituximab in High-Risk R/R Follicular Lymphoma

March 31st 2025

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas

March 31st 2025

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma

March 21st 2025

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

March 20th 2025

The FDA granted fast track designation azercabtagene zapreleucel for relapsed/refractory diffuse large B-cell lymphoma.